Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.98 and traded as high as $3.23. Sonoma Pharmaceuticals shares last traded at $3.16, with a volume of 84,647 shares traded.

Sonoma Pharmaceuticals Trading Up 7.8 %

The stock’s fifty day simple moving average is $2.39 and its two-hundred day simple moving average is $0.98.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Thursday, August 8th. The company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). Sonoma Pharmaceuticals had a negative return on equity of 65.66% and a negative net margin of 35.91%. The business had revenue of $3.39 million for the quarter. On average, equities analysts predict that Sonoma Pharmaceuticals, Inc. will post -4 earnings per share for the current fiscal year.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.